Cat. #154149
MDA-MB-231 TetOn-3G MRCKBeta cell line
Cat. #: 154149
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 3-4 weeks
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Transgenic
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Daniel Croft ; Justin Bower ; Heather Mckinnon
Institute: Cancer Research UK, Glasgow: The Beatson Institute
Tool Details
*FOR RESEARCH USE ONLY
- Name: MDA-MB-231 TetOn-3G MRCKBeta cell line
- Alternate name: Serine/threonine-protein kinase MRCK beta, CDC42-binding protein kinase beta, CDC42BP-beta, DMPK-like beta, Myotonic dystrophy kinase-related CDC42-binding kinase beta, MRCK beta, Myotonic dystrophy protein kinase-like beta
- Tool sub type: Continuous
- Parental cell: MDA-MB-231 D3H2LN-Luc cell line
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Growth properties: Adherent cell line. Membrane blebbing/cytoskeleton reorganisation and migration induced in the presence of doxycycline.
- Model: Transgenic
- Conditional: Yes
- Conditional description: MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G regulated expression of MRCKÄÂ?Â. Therefore MRCKÄÂ? expression is induced in the presence of doxycycline.
- Description: This cell line has been engineered to enable tetracycline inducible expression of the kinase MRCK?. MRCK? is a myotonic dystrophy kinase-related CDC42-binding kinase involved in regulating actin-myosin contractility and implicated in cancer metastasis. MRCK?, in conjunction with MRCKa, ROCK1 and ROCK2 kinases, initiates signalling events that lead to contractile force generation which powers cancer cell motility and invasion. The cell line is a derivative of a human breast cancer cell lin...
- Biosafety level: 1
- Additional notes: Treatment with doxycycline induced MRCK? kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested. Tet-On System owned by TET Systems GmbH & Co. KG.
- Recommended controls: MDA-MB-231 D3H2LN-Luc parental line
Target Details
- Target: MRCKÄÂ?Â
Handling
- Format: Frozen
- Growth medium: 10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- Unbekandt et al. 2014. Cell Commun Signal. 12:54. PMID: 25288205.
- A novel small-molecule MRCK inhibitor blocks cancer cell invasion.
